Nichols & Pratt Advisers LLP MA Purchases 190 Shares of Repligen Co. (NASDAQ:RGEN)

Nichols & Pratt Advisers LLP MA boosted its position in Repligen Co. (NASDAQ:RGEN) by 8.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 2,555 shares of the biotechnology company’s stock after acquiring an additional 190 shares during the period. Nichols & Pratt Advisers LLP MA’s holdings in Repligen were worth $459,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. raised its stake in Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 146 shares during the period. Signaturefd LLC grew its holdings in Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. Milestone Investment Advisors LLC purchased a new position in Repligen during the 3rd quarter valued at about $61,000. Headlands Technologies LLC purchased a new position in Repligen during the 3rd quarter valued at about $75,000. Finally, Picton Mahoney Asset Management purchased a new position in Repligen during the 4th quarter valued at about $90,000. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on RGEN. Stifel Nicolaus lifted their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. JPMorgan Chase & Co. reduced their target price on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Finally, KeyCorp lifted their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $197.75.

Insider Activity at Repligen

In other Repligen news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO James Bylund sold 4,373 shares of Repligen stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,597 shares of company stock valued at $5,039,532. Corporate insiders own 1.20% of the company’s stock.

Repligen Price Performance

RGEN stock traded up $0.23 during mid-day trading on Friday, hitting $165.12. 131,948 shares of the stock were exchanged, compared to its average volume of 531,470. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The stock has a market capitalization of $9.23 billion, a price-to-earnings ratio of 659.56, a PEG ratio of 5.58 and a beta of 1.03. The business has a fifty day moving average price of $178.64 and a 200 day moving average price of $174.49. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The firm had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business’s quarterly revenue was down 17.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 earnings per share. On average, sell-side analysts anticipate that Repligen Co. will post 1.46 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.